NCT05574400CompletedPhase 2
The Caffeine, Postoperative Delirium, and Change in Outcomes After Surgery (CAPACHINOS-2) Study
Source: ClinicalTrials.gov · Last updated 16 Jul 2026
Brief summary (registry, in English)
The objective of this study is to test the effects of caffeine on neurocognitive and clinical recovery after major surgery. Specifically, this trial tests the primary hypothesis that caffeine will reduce the incidence of postoperative delirium.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 250 (actual)
- First submitted
- 6 Oct 2022
- Start date
- 20 Feb 2023
- Primary completion date
- 16 Apr 2026
- Lead sponsor
- University of Michigan
- Diseases
- Alzheimer disease
- NCT number
- NCT05574400
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 250
- From 20 Feb 2023 to the primary completion date, 16 Apr 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Emergency surgery
- Outpatient surgery
Other illness
- Severe cognitive impairment precluding the capacity for informed consent
- Seizure disorder history
- Intolerance or allergy to caffeine (based on subjective reporting or objective documentation)
- Patients in acute liver failure
- Active carcinoid syndrome
- Severe audiovisual impairment
Other
- Weight \>130 kg (as a 3 mg/kg dose would approach the upper limit of daily intake recommended by the FDA)
- Enrollment in conflicting research study
- Acute kidney injury preoperatively
- Diagnosis of pheochromocytoma
- Non-English speaking
Who the study is looking for
- Adult (\>/= 70 years old) undergoing non-cardiac, non-intracranial neurologic, non-major vascular surgery requiring general anesthesia with a planned admission for at least 48 hours.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Provision of signed and dated informed consent form.
Age in the registry: 70 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Michigan Medicine Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.